Safety of intravenous immunoglobulin for treatment of auto-immune thrombocytopenia.
The incidence of hepatitis and HIV seroconversion has been examined in 64 patients receiving intravenous immunoglobulin (pepsin-treated at pH 4.0) for auto-immune thrombocytopenia. No evidence of HIV seroconversion has been detected. Five patients developed abnormal liver function following treatment. However, in no case could this be directly attributed to the treatment and no patient has developed chronic liver disease.
D001327:Autoimmune Diseases / Q000628:therapy*; D006679:HIV Seropositivity / Q000453:epidemiology; D006525:Hepatitis, Viral, Human / Q000453:epidemiology; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000592:standards / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000188:drug therapy*
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous